Crohns Disease News
|
|
   
|
|
Crohns Disease News Archive20-Dec-2006Research & Markets: One of UCB's biggest-selling Products, Keppra, Achieved Sales Growth of 34% (Business Wire via Yahoo! Finance) DUBLIN, Ireland----Research and Markets has announced the addition of the Espicom Business Intelligence Ltd report: UCB Prospects to 2010 to their offering. PanGenetics B.V. Licenses Therapeutic Antibody for Treatment of Pain from Lay Line Genomics S.p.A. (Business Wire via Yahoo! Finance) UTRECHT, The Netherlands & CAMBRIDGE, England & ROME, Italy----PanGenetics B.V. and Lay Line Genomics S.p.A. jointly announced today that the companies have entered into a collaboration in the field of therapeutic antibodies for the treatment of pain. Elan, Biogen Idec submit Tysabri for Crohn's (Pharmaceutical Business Review) Elan and Biogen Idec have submitted a biologics license application to the FDA seeking approval to market Tysabri in the US as a treatment for Crohns disease. Research & Markets: One of UCB´s biggest-selling Products, Keppra, Achieved Sales Growth of 34% (wallstreet:online AG) Research and Markets (http://www.researchandmarkets.com/reports/c47159) has announced the addition Calendar (Baltimore Sun) Events, screenings, support groups and more
Back to Crohns Disease News Archive
|
|